Do adrenergically active drugs have a role in the first-line treatment of attention-deficit/hyperactivity disorder?

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 12, 2005, Pages 1989-1998

  Hazell, Philip ^a  

^a UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

Adrenergic agonist; Adrenergic uptake inhibitors; Attention deficit hyperactivity disorder; Monoamine oxidase inhibitor; Tricyclic antidepressive agents

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMFEBUTAMONE; AMPHETAMINE; ATOMOXETINE; BUSPIRONE; CLONIDINE; CLORGYLINE; DESIPRAMINE; DEXAMPHETAMINE; GUANFACINE; IMIPRAMINE; LOFEXIDINE; METHYLPHENIDATE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NORTRIPTYLINE; PEMOLINE; PSYCHOSTIMULANT AGENT; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ABDOMINAL PAIN; ANOREXIA; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; COMORBIDITY; CONSTIPATION; DEPRESSION; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DROWSINESS; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DYSPEPSIA; ERECTILE DYSFUNCTION; EUPHORIA; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERTENSION; INSOMNIA; IRRITABILITY; JAUNDICE; LIBIDO DISORDER; LIVER DYSFUNCTION; NAUSEA; NIGHTMARE; QT PROLONGATION; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; STOMACH PAIN; SUSTAINED RELEASE PREPARATION; SWEATING; TACHYCARDIA; TIC; VOMITING; WEIGHT GAIN; WOLFF PARKINSON WHITE SYNDROME; XEROSTOMIA;

ADRENERGIC AGENTS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; HUMANS;

EID: 27744578334     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.12.1989     Document Type: Review

References (62)

1. BARKLEY RA: Major life activity and health outcomes associated with attention-deficit/hyperactivity disorder. J. Clin. Psychiatry (2002) 63(Suppl. 12):10-15.
2. FISCHER M, BARKLEY RA, SMALLISH L, FLETCHER K: Young adult follow-up of hyperactive children: self-reported psychiatric disorders, comorbidity; and the role of childhood conduct problems and teen CD. J. Abnorm. Child Psychol. (2002) 30:463-475.
3. MANNUZZA S, KLEIN RG: Long-term prognosis in attention-deficit/hyperactivity disorder. Child Adolesc. Pychiatr. Clin. N. Am. (2000) 9:711-726.
4. MANNUZZA S, KLEIN RG, BESSLER A, MALLOY P, HYNES ME: Educational and occupational outcome of hyperactive boys grown up. J. Am. Acad. Child Adolesc. Psychiatry (1997) 36:1222-1227.
5. MANNUZZA S, KLEIN RG, BESSLER A, MALLOY P, LAPADULA M: Adult outcome of hyperactive boys: educational achievement, occupational rank, and psychiatric status. Arch. Gen. Psychiatry (1993) 50:565-576.
6. WEISS G, HECHTMAN L, MILROY T, PERLMAN T: Psychiatric status of hyperactives as adults: a controlled prospective 15-year follow-up of 63 hyperactive children. J. Am. Acad. Child Adolesc. Psychiatry (1985) 24:211-220.
7. GRAETZ BW, SAWYER MG, HAZELL PL, ARNEY F, BAGHURST P: Validity of DSM-IVADHD subtypes in a nationally representative sample of Australian children and adolescents. J. Am. Acad. Child Adolesc. Psychiatry (2001) 40:1410-1417.
8. JENSEN PS, KETTLE L, ROPER MT et al.: Are stimulants overprescribed? Treatment of ADHD in four US communities. J. Am. Acad. Child Adolesc. Psychiatry (1999) 38:797-804.
9. SAWYER MG, REY JM, GRAETZ BW, CLARK JJ, BAGHURST PA: Use of medication by young people with attention-deficit/hyperactiviry disorder. Med. J. Aust. (2002) 177:21-25.
10. AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY: Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry (1997) 36:85S-121S.
11. HAZELL P: A review of the newer compounds available in Australia for the treatment of attention-deficit/hyperactivity disorder. Australasian Psychiatry (2004) 12:369-375.
12. HUNT RD, MINDERAA RB, COHEN DJ: Clonidine benefits children with attention deficit disorder and hyperactivity: report ofa double-blind placebo-crossover therapeutic trial. J. Am. Acad. Child Adolesc. Psychiatry (1985) 24:617-629.
13. LEVY F, FARROW M: Working memory in ADHD: prefrontal/parietal connections. Current Drug Targets (2001) 2:347-352.
14. VIGGIANO D, RUOCCO LA, ARCIERI S, SADILE AG: Involvement of norepinephrine in the control of activity and attentive processes in animal models of attention deficit hyperactivity disorder. Neural Plasticity (2004) 11:133-149.
15. BARR CL, KROFT J, FENG Y et al: The norepinephrine transporter gene and attention-deficit hyperactivity disorder. Am. J. Med. Genetics (2002) 114:255-259.
16. REEVES G, SCHWEITZER J: Pharmacological management of attention-deficit hyperactivity disorder. Expert Opin. Pharmacother. (2004) 5:1313-1320.
17. PLISZKA SR: Non-stimulant treatment of attention-deficit/hyperactivity disorder. CNS Spectrums (2003) 8:253-258.
18. SAWYER MG, REY JM, G RAETZ BW, CLARK JJ, BAGHURST PA: Use of medication by young people with attention-deficit/hyperactivity disorder. Med. J. Aust. (2002) 177:21-25.
19. CONNOR DF, BARKLEY RA, DAVIS HT: A pilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder. Clin. Pediatr. (2000) 39:15-25.
20. CONNOR DF, FLETCHER KE, SWANSON JM: A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry (1999) 38:1551-1559.
21. AGARWAL V, SITHOLEY P, KUMAR S, PRASAD M: Double-blind, placebo-controlled trial of clonidine in hyperactive children with mental retardation. Ment. Retard. (2001) 39:259-267.
22. JASELSKlS CA, COOK EH JR, FLETCHER KE, LEVENTHAL BL: Clonidine treatment of hyperactive and impulsive children with autistic disorder. J. Clin. Psychopharmacol. (1992) 12:322-327.
23. TAYLOR FB, RUSSO J: Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder. J. Clin. Psychopharmacol. (2001) 21:223-238.
24. SCAHILL L, CHAPPELL PB, KIM YS et al.: A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am. J. Psychiatry (2001) 158:1067-1074.
25. NIEDERHOFER H, STAFFEN W, MAIR A: A placebo-controlled study of lofexidine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. J. Psychopharmacol. (2003) 17:113-119.
26. ZAMETKIN A, RAPOPORT JL, MURPHY DL, LINNOILA M, ISMOND D: Treatment of hyperactive children with monoamine oxidase inhibitors: I. Clinical efficacy. Arch. Gen. Psychiatry (1985) 42:962-966.
27. ANTKOWIAK R, RAJEWSKI A: [Administration of moclobemide++ in children with attention deficit hyperactivity disorder]: [Polish]. Psychiatr. Pol. (1998) 32:751-757.
28. MYRONUK LD, WEISS M, COTTER L: Combined treatment with moclobemide and methylphenidate for comorbid major depression and adult attention-deficit/hyperactivity disorder. J. Clin. Psychopharmacol. (1996) 16:468-469.
29. VAIVA G, DE LENCLAVE MB, BAILLY D: Treatment of comorbid opiate addiction and attention-deficit hyperactivity disorder (residual type) with moclobemide: a case report. Prog. Neuropsychopharmacol. Biol. Psychiatry (2002) 26:609-611.
30. TROTT GE, FRIESE HJ, MENZEL M, NISSEN G: Use of moclobemide in children with attention deficit hyperactivity disorder. Psychopharmacol. (1992) 106(Suppl.):S134-S136.
31. JADAD AR, BOYLE M, CUNNINGHAM C, KIM M, SCHACHAR R: Treatment of attention-deficit/hyperactivity disorder. Evidence Report: Technology Assessment No. 11, National Library of Medicine, Washington (2001).
32. PRINCE JB, WILENS TE, BIEDERMAN J et al.: A controlled study of nortriptyline in children and adolescents with attention deficit hyperactivity disorder. J. Child Adolesc. Psychopharmacol. (2000) 10:193-204.
33. OLVERA RL, PLISZKA SR, LUH J, TATUM R: An open trial of venlafaxine in the treatment of attention-deficit/hyperactivity disorder in children and adolescents. J Child Adolesc. Pychopharmacol. (1996) 6:241-250.
34. FINDLING RL, SCHWARTZ MA, FLANNERY DJ, MANOS MJ: Venlafaxine in adults with attention-deficit/hyperactivity disorder: an open clinical trial. J. Clin. Psychiatry (1996) 57:184-189.
35. RATNER S, LAOR N, BRONSTEIN Y, WEIZMAN A, TOREN P: Six-week open-label Reboxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry (2005) 44:428-433.
36. OTKA JE, MERCADANTE MT, SCAHILL L, LECKMAN JF: Reboxetine as a potentially effective treatment for attention deficit hyperactivity disorder. J. Child Adolesc. Psychopharmacol. (2001) 11:203-204.
37. MICHELSON D, ALLEN AJ, BUSNER J et al.: Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am. J. Psychiatry (2002) 159:1896-1901.
38. SPENCER T, BIEDERMAN J, WILENS T et al.: Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am. J. Psychiatry (1998) 155:693-695.
39. MICHELSON D, ADLER L, SPENCER T et al.: Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol. Psychiatry (2003) 53:112-120.
40. MICHELSON D, FARIES D, WERNICKE J et al.: Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics (2001) 108:E83.
41. SPENCER T, HEILIGENSTEIN JH, BIEDERMAN J et al.: Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J. Clin. Psychiatry (2002) 63:1140-1147.
42. KRATOCHVIL CJ, HEILIGENSTEIN JH, DITTMANN R et al.: Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J. Am. Acad. Child Adolesc. Psychiatry (2002) 41:776-784.
43. ALLEN A, MILTON D, MICHELSON D, KELSEY D: Efficacy of atomoxetine treatment for adolescents with attention-deficit/hyperactivity disorder: poster presented at Annual Meeting of the American Psychiatric Association. May 17-22, 2003, San Francisco, California, USA.
44. BIEDERMAN J, HEILIGENSTEIN JH, FARIES DE et al.: Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder. Pediatrics (2002) 110:E75.
45. HAZELL PL, STUART JE: A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. J. Am. Acad. Child Adolesc. Psychiatry (2003) 42:886-894.
46. TOURETTE'S SYNDROME STUDY GROUP: Treatment of ADHD in children with tics: a randomized controlled trial. Neurology (2002) 58:527-536.
47. STEINGARD R, BIEDERMAN J, SPENCER T, WILENS T, GONZALEZ A: Comparison of clonidine response in the treatment of attention-deficit hyperactivity disorder with and without comorbid tic disorders. J. Am. Acad. Child Adolesc. Psychiatry (1993) 32:350-353.
48. SPENCER T, BIEDERMAN J, COFFEY B et al.: A double-blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention-deficit/hyperactivity disorder. Arch. Gen. Psychiatry (2002) 59:649-656.
49. HEIL SH, HOLMES HW, BICKEL WK et al.: Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug Alcohol Depend. (2002) 67:149-156.
50. NEWCORN JH SPENCER TJ, BIEDERMAN J, MILTON DR, MICHELSON D: Atomoxetine treatment in children and adolescents with attention-defict/hyperactivity disorder and comorbid oppositional defiant disorder. J. Am. Acad. Child Adolesc. Psychiatry (2005) 44:240-248.
51. FELDMAN PD, RUFF DD, ALLEN AJ: Atomoxetine and tics in ADHD. J. Am. Acad. Child Adolesc. Psychiatry (2005) 44:405-6.
52. RAMCHANDANI P, JOUGHIN C, ZWI M: Attention deficit hyperactivity disorder. Clin. Evidence (2003) 9:318-27.
53. CANTWELL DP, SWANSON J, CONNOR DF: Case study: adverse response to clonidine. J. Am. Acad. Child Adolesc. Psychiatry (1997) 36:539-44.
54. PEARSON CC: Self-induced overdose of ADHD medication. J. Paediatr. Child Health (1996) 32:267
55. KAPPAGODA C, SCHELL DN, HANSON RM, HUTCHINS P: Clonidine overdose in childhood: implications of increased prescribing. J. Paediatr. Child Health (1998) 34:508-512.
56. ERICKSON SJ, DUNCAN A: Clonidine poisoning-an emerging problem: epidemiology, clinical features, management and preventative strategies. J. Paediatr. Child Health (1998) 34:280-282.
57. ALDERTON HR: Tricyclic medication in children and the QT interval: case report and discussion. Can. J. Psychiatry (1995) 40:325-329.
58. CABALLERO J, NAHATA MC: Atomoxetine hydrochloride for the treatment of attention-deficit/hyperactivity disorder. Clin. Ther. (2003) 25:3065-3083.
59. WERNICKE JF, KRATOCHVIL CJ: Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. J. Clin. Psychiatry (2002) 63(Suppl. 12):50-55.
60. PATRICK KS, GONZALEZ MA, STRAUGHN AB: New methylphenidate formulations for the treatment of attention-deficit/hyperactivity disorder. Expert Opin. Drug Delivery (2005) 2:121-143.
61. SPENCER TJ, BIEDERMAN J, WILENS TE, FARAONE SV: Novel treatments for attention-deficit/hyperactivity disorder in children. J. Clin. Psychiatry (2002) 12:16-22.
62. HAZELL P: In children with attention-deficit hyperactivity disorder who have been taking methylphenidate for at least 1 year, is there any evidence of harmful effects? Evidence-Based Healthcare and Public Health (2005) 9:10-15.